Lesiones serradas: clasificación y seguimiento

Dr. Antoni Castells Servicio de Gastroenterología Hospital Clínic, Barcelona (castells@clinic.cat)










Colorectal polyps


- Non-neoplastic hyperplastic polyps (HPs)
- Neoplastic adenomas (tubular, tubulovillous, villous), cytologic dysplasia → adenoma-carcinoma sequence



 Jass (1983): relationship between HPs and CRC → HP-carcinoma sequence

Serrated lesions

- Heterogeneous group of polyps with serrated morphology
- Variable shape of CRC precursors → the word "lesion" is preferred
- Significant risk for neoplastic progression → 20-25% of sporadic or non-syndromic CRC (mainly proximal colon)



Histologic classification of serrated lesions

Odze and Hornick 2009 ²⁸ : type and synonym	Snover et al ²³ : type and synonym
I. Nondysplastic	
A. Normal architecture, normal proliferation	
Hyperplastic polyps a. Goblet cell hyperplastic polyp b. Microvesicular hyperplastic polyp c. Mucin-poor hyperplastic polyp	Hyperplastic/metaplastic polyp Microvesicular hyperplastic polyp Goblet cell hyperplastic polyp
3. Abnormal architecture, abnormal proliferation	
Sessile serrated polyp	Sessile serrated adenoma/polyp serrated polyp with abnormal proliferation
I. Dysplastic	
 A. Serrated adenoma (traditional) B. Sessile serrated polyp with dysplasia mixed polyp, advanced sessile serrated polyp C. Conventional adenoma with serrated architecture 	Traditional serrated adenoma serrated adenoma filiform serrated adenoma Sessile serrated adenoma/polyp with dysplasia mixed hyperplastic-adenomatous polyp advanced sessile serrated adenoma/polyp

Orlowska J. Gastrointest Endosc 2013

Clinical characteristics of serrated lesions


- Hyperplastic polyps (HP)
 - 75% of serrated lesions
 - Sessile, pale-appearing, <5 mm
 - Common in rectosigmoid area → no malignant transformation
 - "High-risk" HPs: multiplicity(>20), >10 mm, proximal location, family history
- Sessile serrated adenomas (SSA)
 - 15-20% of serrated lesions
 - Sessile, pale-appearing lesion covered by mucus, >5 mm
 - Common in proximal colon
 - Female predominance, associated with aging



Clinical characteristics of serrated lesions


- Traditional serrated adenomas (TSA)
 - 1-6% of serrated lesions
 - Location: rectosigmoid (60%)
 - Pedunculated, >5 mm (>10 mm in the right colon)
 - Rate of malignant transformation similar to adenomas, and related to the size and location → large, proximal TSA may progress more rapidly

Sessile serrated pathway



Goel and Balaguer. Curr CRC Rep 2011

Alternative serrated pathway



Goel and Balaguer. Curr CRC Rep 2011

Endoscopic detection of serrated lesions

Detection rate of proximal serrated polyps in screening colonoscopy

Endoscopist	Number of colonoscopies	Patient age ^a	Male	≥1 Adenoma	≥ 1 Proximal serrated polyp	Adenoma detection rate per colonoscopy ^a	Proximal serrated polyp detection rate per colonoscopy ^a
1	3189	59.8 ± 8.0	52%	47%	18%	1.06 ± 1.79	0.26 ± 0.68
2	154	57.8 ± 8.0	45%	31%	10%	0.76 ± 1.59	0.14 ± 0.46
3	532	57.4 ± 7.3	45%	33%	6%	0.73 ± 1.57	0.08 ± 0.35
4	109	58.2 ± 7.0	46%	39%	11%	0.86 ± 1.46	0.18 ± 0.55
5	331	57.4 ± 6.9	48%	40%	13%	0.77 ± 1.36	0.18 ± 0.53
6	124	58.4 ± 6.9	44%	33%	8%	0.77 ± 1.66	$\textbf{0.11} \pm \textbf{0.41}$
7	528	58.9 ± 7.7	41%	31%	11%	0.69 ± 1.47	0.16 ± 0.48
8	56	59.2 ± 7.6	50%	46%	13%	1.20 ± 1.86	0.14 ± 0.40
9	348	57.7 ± 7.5	37%	36%	12%	0.74 ± 1.48	0.17 ± 0.52
10	359	57.7 ± 7.3	53%	25%	3%	0.45 ± 1.05	0.04 ± 0.20
11	90	57.7 ± 6.7	52%	17%	1%	0.22 ± 0.56	$\textbf{0.01} \pm \textbf{0.11}$
12	83	59.1 ± 8.3	52%	27%	2%	0.46 ± 0.98	0.02 ± 0.15
13	327	58.1 ± 7.8	60%	29%	11%	0.50 ± 0.95	0.15 ± 0.49
14	297	59.5 ± 8.2	50%	21%	4%	$\textbf{0.38} \pm \textbf{1.07}$	0.06 ± 0.37
15	154	57.8 ± 8.0	45%	31%	10%	0.76 ± 1.59	0.14 ± 0.46
Combined	6681	58.9 ± 7.8	49%	38%	13%	$\textbf{0.84} \pm \textbf{1.60}$	0.19 ± 0.57

^aMean ± SD.

Kahi et al. Clin Gastroenterol Hepatol 2011

Endoscopic detection of serrated lesions

Detection rate of proximal serrated polyps per endoscopist


Comparison (vs endoscopist 1)	Odds ratio (95% CI)	P value
Endoscopist 2	0.50 (0.29–0.85)	.0114
Endoscopist 3	0.31 (0.21–0.44)	<.0001
Endoscopist 4	0.57 (0.31–1.05)	.0701
Endoscopist 5	0.67 (0.48–0.94)	.0198
Endoscopist 6	0.40 (0.21-0.78)	.0066
Endoscopist 7	0.59 (0.45–0.79)	.0003
Endoscopist 8	0.66 (0.30-1.46)	.3055
Endoscopist 9	0.65 (0.47-0.91)	.0111
Endoscopist 10	0.16 (0.09-0.29)	<.0001
Endoscopist 11	0.05 (0.01-0.37)	.0033
Endoscopist 12	0.11 (0.03–0.46)	.0025
Endoscopist 13	0.57 (0.40-0.82)	.0021
Endoscopist 14	0.19 (0.11-0.35)	<.0001
Endoscopist 15	0.50 (0.29–0.85)	.0114

CI, confidence interval.

Kahi et al. Clin Gastroenterol Hepatol 2011

Endoscopic appearance of serrated lesions

- Frequently flat or sessile
- Covered by mucus
- Overlooked during colonoscopy: missed lesions → interval CRC
 - Right sided
 - Microsatellite instability (MSI)
 - CIMP-H



Risk of malignant transformation


Large serrated polyps (LSPs) as predictive factors of advanced neoplasia

	Subjects without advanced neoplasia (n = 8626)	Subjects with advanced neoplasia (n = 1573)	Univariate analysis, OR (95% Cl)
Age	57.7 ± 15.1	65.2 ± 12.0	
<65 y	5487	730	1.00
$\geq 65 y$	3139	843	2.02 (1.81–2.25) ^b
Gender			
Female	4348	594	1.00
Male	4278	979	1.68 (1.50–1.87) ^b
Number of small ademonas ^a			
0–3	8537	1470	1.00
≥4	89	103	6.72 (5.03-8.97) ^b
LSPs			
No	8548	1511	1.00
Yes	78	62	4.50 (3.21–6.30) ^b

Hiraoka et al. Gastroenterology 2010

Risk of malignant transformation (I)

Large serrated polyps (LSPs) as predictive factor of advanced neoplasia



Hiraoka et al. Gastroenterology 2010

Risk of malignant transformation (I)

Predictive factors of advanced neoplasia according to location (multivariate analysis)

Variables	Distal advanced neoplasia, OR (95% CI)	Proximal advanced neoplasia, OR (95% CI)
Age ≥65 Male gender Number of small	$1.76 (1.55-2.00)^{b}$ $1.72 (1.52-1.97)^{b}$ $3.74 (2.74-5.08)^{b}$	2.05 (1.72–2.43) ^b 1.34 (1.13–1.60) ^c 4.85 (3.41–6.79) ^b
ademonas ≥4 ^a LSPs	2.96 (2.01–4.29) ^b	3.63 (2.29–5.55) ^b

Hiraoka et al. Gastroenterology 2010

Risk of malignant transformation (II)

ColonPrev study (colonoscopy arm, 5,059 individuals)

Patients with serrated polyps‡	1054 (20.8)
No. of serrated polyps/patient	
1	588 (11.6)
2	223 (4.4)
3	110 (2.2)
4	48 (0.9)
≥5	85 (1.7)
Proximal§ serrated polyps‡	329 (6.5)
Large serrated polyps‡	90 (1.8)
Large serrated proximal polyps‡	36 (0.7)

Alvarez et al. Gastrointest Endosc 2013

Risk of malignant transformation (II)

TABLE 3. Predictive factors of advanced neoplasiaaccording to location (multivariate analysis)

Variable	Proximal* advanced neoplasia† OR (95% CI)	Distal advanced neoplasia† OR (95% CI)
Serrated polyps‡		
No		1
Yes		1.49 (1.15-1.95)
Large§ serrated polyps‡		
No	1	1
Yes	4.15 (1.69-10.15)	2.61 (1.48-4.58)

Alvarez et al. Gastrointest Endosc 2013

Risk of malignant transformation (III)


Prevalence of advanced / multiple adenomas in patients with and without proximal and large serrated polyps

Baseline	Advanced adenoma	≥3 Tubular adenomas ^a
Proximal ND-SP	17.3	10.7
(n = 248), %		
No Proximal ND-SP	10.0	5.3
(n = <mark>2873),</mark> %		
OR (95% CI)	1.90 (1.33-2.70)	2.19 (1.36-3.52)
Large ND-SP (n = 44), %	27.3	9.4
No Large ND-SP	10.3	5.6
(n = 3077), %		
OR (95% CI)	3.37 (1.71-6.65)	1.72 (0.52-5.73)

Schreiner et al. Gastroenterology 2010

Risk of malignant transformation (III)

Prevalence of advanced / multiple adenomas in patients with and without proximal and large serrated polyps



Schreiner et al. Gastroenterology 2010

Risk of malignant transformation (III)

Proximal serrated polyps as a risk factor of advanced neoplasia on follow-up

Findings on baseline CSP	Baseline CSP (n)	Subjects with follow-up CSP, n (%)	Advanced neoplasia on follow-up CSP, n (%)	OR (95% CI)
No neoplasia	1950	454		
With proximal ND-SP	118	39 (33.1)	2 (5.1)	2.09 (0.44-9.87)
Without proximal ND-SP	1832	415 (22.6)	11 (2.7)	
Small tubular adenoma	842	634		
<10 mm				
With proximal ND-SP	87	63 (72.4)	5 (7.9)	1.23 (0.46-3.28)
Without proximal ND-SP	755	571 (75.6)	36 (6.3)	
Advanced neoplasia	329	283		
With proximal ND-SP	43	38 (88.4)	11 (28.9)	2.25 (1.02-4.96)
Without proximal ND-SP	286	245 (85.7)	36 (14.7)	


Schreiner et al. Gastroenterology 2010

Surveillance strategies in serrated lesions

TABLE 3. Guidelines for colorectal carcinoma colonoscopy screening and surveillance after the removal of serrated lesions according to the European Union¹⁵ and National Comprehensive Cancer Network⁷²⁻⁷⁴ recommendations, and the risk of malignant transformation¹⁴


Diagnosis	Risk of colorectal carcinoma ¹⁴	Interval for control**†
Hyperplastic polyp	None	No indication for follow-up
Sessile serrated lesion	Slightly increased, but exact data are missing	5 or 3 or 1 y
Traditional serrated adenoma	Increased	5 or 3 or 1 y

Surveillance strategies in serrated lesions (ASGE)



Rex et al. Am J Gastroenterol 2012

Surveillance strategies in adenomas and serrated lesions (ESGE)



¹High risk group: patients with an adenoma ≥10 mm; or with high-grade dysplasia; or a villous component; or ≥3 adenomas; and patients with a serrated lesion ≥10mm or with dysplasia.

Risk stratification of patients with colorectal adenomas and/or serrated polyps, and postpolypectomy surveillance

Risk stratum	Diagnostic criteria ²	Surveillance strategy
No-risk lesions	Hyperplastic polyps < 10 mm limited to rectum and sigmoid colon	Return to the screening program
Low-risk lesions ³	 1 - 2 tubular adenomas < 10 mm with low-grade dysplasia, or 1 - 2 serrated polyps < 10 mm without dysplasia^{4, 5} 	Return to the screening program
Intermedi- ate-risk lesions ⁶	3 – 4 tubular adenomas < 10 mm with low-grade dysplasia, or 1 – 4 tubular adenomas 10 – 19 mm with low-grade dysplasia, or 1 – 4 adenomas < 20 mm with villous component, and/or high-grade dysplasia, and/or intramucosal carcinoma, or 3 – 4 serrated polyps < 10 mm without dysplasia ^{4, 5} , or 1 – 4 serrated polyps 10 – 19 mm without dysplasia ^{4, 5} , or 1 – 4 serrated polyps < 20 mm with dysplasia ^{4, 5}	Colonoscopy at 3 years
High-risk lesions	≥5 adenomas/serrated polyps ⁴ , or ≥1 adenoma/serrated polyp ⁴ ≥20 mm	Colonoscopy at 1 year ⁷

Castells et al. Endoscopy 2015

Summary

- Serrated lesions are the precursors of up to one-third of CRC
- CRC arising in serrated lesions are usually in the proximal colon
- Serrated lesions should be classified in HP, SSA with and without dysplasia, and TSA (WHO criteria)
- Serrated lesions have a distinct endoscopic appearance, and they are more difficult to detect
- Recommendations for postpolypectomy surveillance are mostly based on features of serrated lesions associated with increased risk of advanced neoplasms.

Lesiones serradas: clasificación y seguimiento

Dr. Antoni Castells Servicio de Gastroenterología Hospital Clínic, Barcelona (castells@clinic.cat)







